Liver transplantation for viral hepatitis

Area of Science:

• Hepatology
• Transplantation Immunology
• Infectious Diseases

Background:

• Liver transplantation offers survival rates of 73-83% (elective) and 55-70% (emergency), making it a viable treatment for end-stage chronic liver disease and acute liver failure.
• Early identification of acute liver failure candidates is crucial, with clinical criteria models aiding selection.
• Recurrent viral infections, particularly hepatitis B, pose a significant threat post-transplantation across patient subgroups.

Purpose of the Study:

• To evaluate the impact of recurrent viral infections on post-liver transplantation survival.
• To explore potential protective factors against recurrent infections, such as delta virus co-infection.
• To highlight the need for improved strategies in managing post-transplant viral recurrence.

Main Methods:

• Analysis of survival data for 29 patients surviving at least 60 days post-liver transplantation.
• Review of clinical criteria for selecting acute liver failure patients.
• Examination of infection recurrence patterns, focusing on hepatitis B and delta virus.

Main Results:

• 41% of patients who survived the initial 60 days post-transplant died between 3-13 months due to recurrent viral infections.
• Chronic hepatitis B infection demonstrated the clearest manifestation of recurrent infection.
• Delta virus infection appeared to offer some protection against recurrent viral infections.

Conclusions:

• Recurrent viral infections, especially hepatitis B, are a major cause of mortality after liver transplantation.
• Delta virus co-infection may play a protective role, warranting further investigation.
• The efficacy of long-term immunoprophylaxis in preventing post-transplant viral recurrence requires further study.